<DOC>
	<DOC>NCT02945228</DOC>
	<brief_summary>The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir with ribavirin used for participants infected with chronic hepatitis C virus (HCV) genotype 2 in daily practice in Japan.</brief_summary>
	<brief_title>Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>HCV genotype 2 participants treated with paritaprevir/ritonavir/ombitasvir plus ribavirin in daily practice. Participants who have been previously treated with paritaprevir/ritonavir/ombitasvir and ribavirin.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Paritaprevir</keyword>
	<keyword>Genotype 2</keyword>
	<keyword>Hepatitis C Virus (HCV)</keyword>
	<keyword>Ombitasvir</keyword>
	<keyword>Ritonavir</keyword>
</DOC>